Immunic (NASDAQ:IMUX) Given Buy Rating at D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of Immunic (NASDAQ:IMUX) in a research note published on Thursday,Benzinga reports. They currently have a $17.00 price objective on the stock.

IMUX has been the subject of a number of other reports. StockNews.com lowered shares of Immunic from a “hold” rating to a “sell” rating in a research report on Monday, February 10th. HC Wainwright assumed coverage on Immunic in a report on Monday, November 25th. They set a “buy” rating and a $10.00 price objective on the stock. One analyst has rated the stock with a sell rating, six have assigned a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $12.67.

Immunic Stock Up 12.4 %

Shares of IMUX stock opened at $1.18 on Thursday. Immunic has a one year low of $0.92 and a one year high of $2.11. The stock has a fifty day moving average price of $1.02 and a 200 day moving average price of $1.26.

Institutional Trading of Immunic

Large investors have recently added to or reduced their stakes in the company. Jane Street Group LLC boosted its holdings in shares of Immunic by 121.4% in the 3rd quarter. Jane Street Group LLC now owns 70,299 shares of the company’s stock worth $116,000 after acquiring an additional 38,553 shares in the last quarter. HB Wealth Management LLC bought a new position in Immunic in the 4th quarter valued at $81,000. State Street Corp boosted its stake in Immunic by 7.5% in the third quarter. State Street Corp now owns 167,145 shares of the company’s stock worth $276,000 after purchasing an additional 11,642 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. grew its holdings in shares of Immunic by 70.8% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 102,257 shares of the company’s stock worth $169,000 after purchasing an additional 42,383 shares during the last quarter. Finally, Virtu Financial LLC acquired a new stake in shares of Immunic in the third quarter valued at $50,000. 51.82% of the stock is owned by institutional investors.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.